Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for body dysmorphic disorder
ACTRN12622000429752Phase 2Recruiting
- Sponsor
- Swinburne University of Technology
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of oxytocin, sponsored by Swinburne University of Technology. Started Sep 2022; status: recruiting.
02
Drugs
oxytocin
Beyond the preview
Go deeper on ACTRN12622000429752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000429752.